Here, we present evidence showing clear differences in NFκB response that parallel the epidemiological data, supporting the notion that the ability of aspirin to modulate the NFκB signalling pathway is a key determinant of the anti-tumour effect and that this is cell-type specific. The gene discussed is NFKB1; the disease is neoplasm.